Lindahl B, Alm P, Fernö M, Killander D, Långström E, Norgren A, Trope C
Department of Obstetrics and Gynecology, University Hospital, Lund, Sweden.
Anticancer Res. 1987 Jul-Aug;7(4B):791-7.
The prognostic value of flow cytometric DNA measurements of individual tumor cells was studied in 166 patients with endometrial carcinoma stage I-II. Follow-up time was 1-46 months and 110 patients were followed for more than 2 years. Three different ways of estimating DNA ploidy were evaluated, and the use of normal endometria in defining diploidy was considered the best. DNA-ploidy had a much more marked prognostic value in terms of 2-year recurrence-free survival than other known prognostic parameters, such as degree of differentiation, range of myometrial invasion and estradiol and progesterone receptor concentrations. The proliferative activity as determined by DNA flow cytometrical analysis was not correlated with prognosis.
对166例Ⅰ - Ⅱ期子宫内膜癌患者的单个肿瘤细胞进行流式细胞术DNA测量的预后价值进行了研究。随访时间为1 - 46个月，110例患者随访时间超过2年。评估了三种不同的DNA倍体估计方法，认为使用正常子宫内膜来定义二倍体是最佳方法。就2年无复发生存率而言，DNA倍体比其他已知的预后参数，如分化程度、肌层浸润范围以及雌二醇和孕酮受体浓度，具有更为显著的预后价值。通过DNA流式细胞术分析确定的增殖活性与预后无关。
